Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucosal vaccine development for botulinum intoxication.

Kohtaro Fujihashi1, Herman F Staats, Shunji Kozaki

  • 1Department of Pediatric Dentistry, The Immunobiology Vaccine Center, The University of Alabama at Birmingham, AL, USA. kohtarof@uab.edu

Expert Review of Vaccines
|February 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection.

RSC pharmaceutics·2026
Same author

Cationic nanogel-based nasal therapeutic HPV vaccine prevents the development of cervical cancer.

Science translational medicine·2025
Same author

Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.

Clinical and experimental vaccine research·2025
Same author

Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines.

Scientific reports·2024
Same author

MucoRice-CTB line 19A, a new marker-free transgenic rice-based cholera vaccine produced in an LED-based hydroponic system.

Frontiers in plant science·2024

Developing mucosal vaccines against botulinum neurotoxins (BoNTs) is crucial for preventing bioterrorism. Mucosal immunization offers superior protection against airborne BoNTs compared to traditional vaccines.

Area of Science:

  • * Microbiology and immunology
  • * Vaccinology
  • * Biodefense

Background:

  • * Botulism, traditionally food-borne, is now a Category A bioterrorism threat due to airborne botulinum neurotoxins (BoNTs).
  • * Current vaccines provide only systemic immunity, leaving mucosal surfaces vulnerable to airborne agents.
  • * The mucosal immune system is the primary defense against airborne pathogens and toxins.

Purpose of the Study:

  • * To highlight the urgent need for effective mucosal vaccines against BoNTs.
  • * To review current advancements in developing mucosal vaccines for botulism.
  • * To emphasize the potential of mucosal immunization in preventing BoNT intoxication.

Main Methods:

  • * Review of existing literature on botulism, BoNTs, and mucosal immunology.

Related Experiment Videos

  • * Analysis of current research on nasal and oral immunization strategies against BoNTs.
  • * Discussion of the efficacy of mucosal vaccines in preclinical models.

    • Main Results:

    • * Mucosal immunization strategies, including nasal and oral routes, have shown promise in preventing BoNT intoxication.
    • * Mucosal vaccines can induce both local and systemic immunity, offering broader protection.
    • * Current research indicates the effectiveness of mucosal vaccines in preventing BoNT exposure via mucosal surfaces.

    Conclusions:

    • * Development of safe and effective mucosal vaccines against BoNTs is a high priority for biodefense.
    • * Mucosal immunization represents a promising approach to combatting airborne BoNT threats.
    • * Further research into BoNT mucosal vaccines is essential to enhance public health security.